- Home
- LUCY vs CVKD Comparison
LUCY vs CVKD Comparison
Compare LUCY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- CVKD
- Stock Information
- Founded
- LUCY 2017
- CVKD 2022
- Country
- LUCY United States
- CVKD United States
- Employees
- LUCY N/A
- CVKD N/A
- Industry
- LUCY Ophthalmic Goods
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- LUCY Health Care
- CVKD Health Care
- Exchange
- LUCY Nasdaq
- CVKD Nasdaq
- Market Cap
- LUCY 8.7M
- CVKD 27.0M
- IPO Year
- LUCY 2022
- CVKD 2023
- Fundamental
- Price
- LUCY $1.72
- CVKD $12.92
- Analyst Decision
- LUCY
- CVKD Strong Buy
- Analyst Count
- LUCY 0
- CVKD 1
- Target Price
- LUCY N/A
- CVKD $32.00
- AVG Volume (30 Days)
- LUCY 144.2K
- CVKD 25.1K
- Earning Date
- LUCY 11-14-2025
- CVKD 11-07-2025
- Dividend Yield
- LUCY N/A
- CVKD N/A
- EPS Growth
- LUCY N/A
- CVKD N/A
- EPS
- LUCY N/A
- CVKD N/A
- Revenue
- LUCY $1,978,018.00
- CVKD N/A
- Revenue This Year
- LUCY $149.32
- CVKD N/A
- Revenue Next Year
- LUCY $400.00
- CVKD N/A
- P/E Ratio
- LUCY N/A
- CVKD N/A
- Revenue Growth
- LUCY 29.30
- CVKD N/A
- 52 Week Low
- LUCY $1.57
- CVKD $8.74
- 52 Week High
- LUCY $10.40
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- LUCY 39.47
- CVKD 50.04
- Support Level
- LUCY $1.72
- CVKD $12.74
- Resistance Level
- LUCY $1.91
- CVKD $13.49
- Average True Range (ATR)
- LUCY 0.10
- CVKD 0.75
- MACD
- LUCY -0.01
- CVKD -0.09
- Stochastic Oscillator
- LUCY 15.00
- CVKD 54.14
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.